ARQ-154 is a small molecule commercialized by Arcutis Biotherapeutics, with a leading Phase III program in Seborrhea. According to Globaldata, it is involved in 5 clinical trials, which were completed. GlobalData uses proprietary data and analytics to provide a complete picture of ARQ-154’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for ARQ-154 is expected to reach an annual total of $349 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
ARQ-154 is under development for the treatment of seborrheic dermatitis, scalp psoriasis and plaque psoriasis.The drug candidate is formulated as a foam and administered by topical route. It acts by targeting phosphodiesterase 4 (PDE4).
Arcutis Biotherapeutics Overview
Arcutis Biotherapeutics (Arcutis) is a biopharmaceutical company. It is focused on developing small molecules for the treatment of immune-mediated dermatological diseases and conditions. The company’s pipeline products include ARQ-151, a topical roflumilast cream for treating plaque psoriasis and atopic dermatitis (eczema); ARQ-154, a topical roflumilast foam against seborrheic dermatitis and scalp psoriasis; ARQ-252, a small molecule inhibitor of Janus kinase type 1 (JAK1) to treat rheumatoid arthritis, psoriasis, Crohn’s disease and atopic dermatitis and ARQ-255 for inflammation in alopecia areata. It is investigating novel dermatology treatments in inflammation and immunology diseases. Arcutis is headquartered in Westlake Village, California, the US.
The operating loss of the company was US$206.5 million in FY2021, compared to an operating loss of US$136.7 million in FY2020. The net loss of the company was US$206.4 million in FY2021, compared to a net loss of US$135.7 million in FY2020.
For a complete picture of ARQ-154’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.